Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of foxm1 inhibitor fdi-6 against liver fibrosis

An FDI-6, anti-liver fibrosis technology, applied in the digestive system, medical preparations containing active ingredients, pharmaceutical formulations, etc.

Active Publication Date: 2019-09-27
NANHUA UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So, whether FOXM1 is associated with liver fibrosis has not been reported so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of foxm1 inhibitor fdi-6 against liver fibrosis
  • Application of foxm1 inhibitor fdi-6 against liver fibrosis
  • Application of foxm1 inhibitor fdi-6 against liver fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: Analyzing clinical samples through the more severe liver fibrosis—cirrhosis tissue gene expression profile (gene expression omnibus, GEO) database on the Internet.

[0036] Experimental materials: two liver cirrhosis databases, GSE25097 and GSE 14323.

[0037] Experimental method: The GEO database GSE25097 and GSE 14323 of liver cirrhosis were investigated online to screen the differential expression of FOXM1.

[0038] Experimental results: Both databases showed that the expression of FOXM1 in cirrhotic tissues was significantly higher than that in normal tissues.

Embodiment 2

[0039] Example 2: Left middle common bile duct ligation (LMBDL) induced liver fibrosis in mice.

[0040] Experimental materials: C57L / 6 mice, 3% sodium pentobarbital solution, surgical instruments.

[0041] Experimental method: 12-week-old male C57BL / 6 mice were anesthetized by intraperitoneal injection of 3% pentobarbital sodium solution, the skin and muscle layer of the abdominal cavity were incised, the common bile duct was freed, the left middle common bile duct was ligated, and the abdominal cavity was sutured.

[0042] Experimental results: After about 10 days, ALT and AST were significantly increased, and HE and Sirius red staining showed obvious liver fibrosis.

Embodiment 3

[0043] Embodiment 3: carbon tetrachloride (CCl 4 ) induced liver fibrosis in mice.

[0044] Experimental materials: C57L / 6 mice, CCl 4 solution, olive oil, 1ml syringe.

[0045] Experimental method: 12-week-old male C57BL / 6 mice were intraperitoneally injected with CCl diluted in olive oil 4 Solution (by volume ratio, CCl 4 : olive oil = 1: 3) twice a week.

[0046] Experimental results: After about 4 weeks, both ALT and AST were significantly increased, and HE and Sirius red staining showed obvious liver fibrosis.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an FOXM1 inhibitor FDI-6 in resistance of hepatic fibrosis. The name of a derivative is 3-amino-N-(4-fluorophenyl)-6-(thiophene-2-ox)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-formamide; an action mechanism is expressed by inhibiting FOXM1; the expression of Collagen I and alpha-SMA is regulated down, so as to realize the corresponding hepatic fibrosis-resistant function. The caused hepatic fibrosis diseases include but not limited to chronic viral hepatitis, alcoholic hepatic diseases, non-alcoholic fatty hepatic diseases, toxin, drug-derived and autoimmunity hepatic diseases, hepatic blood stasis, inherited metabolic diseases and the like.

Description

technical field [0001] The present invention relates to a FOXM1 inhibitor FDI-6 and the application of the compound in anti-hepatic fibrosis. Background technique [0002] Liver fibrosis is closely related to the chronic inflammatory response of the liver, which develops from mild inflammatory response to severe inflammatory response, and finally to liver fibrosis and even cirrhosis. This process includes chronic viral hepatitis, alcoholic liver disease, non-inflammatory Most chronic liver diseases, including alcoholic fatty liver disease, toxins and drugs, autoimmune liver disease, liver congestion and genetic metabolic diseases, etc., follow the common pathological process. Hepatic fibrosis is currently considered to be a reversible pathological process in which the proliferation and degradation of extracellular matrix (ECM) such as collagen in the liver is unbalanced, leading to abnormal deposition of fibrous connective tissue in the liver, reflecting a balanced process o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4365A61P1/16
Inventor 涂剑谢伟全熊婷李子涵张素君杨玉容夏磊廖彩勤
Owner NANHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com